SLITRK5 is a cellular protein whose normal function appears to suppress bone formation and could be a potential new target for the treatment ofosteoporosis, according to a collaborative study conducted by Weill Cornell Medicine and NewYork-Presbyterian researchers.
Cells manifesting the SLITRK5 protein are marked with magenta (left) and a bone-forming osteoblast marker in green (center). These markers were observed in the cancellous bone in the medulla space (top) or on the outer layer covering the bone (bottom). The overlap between these two markers (right) shows that SLITRK5 is found in bone-forming osteoblasts but not in other cell types, helping to make SLITRK5 a target for skeletal disease treatment. Credit: Dr. Matthew Greenblatt and Dr. Jun Sun
There Research was published in the scientific journal Nature Communications.
Read Also
- Unisono implements Speech Analytics | News | Communications May 30, 2021
- Beautiful weekly advances from 6 to 11 September: Steffy is losing control Sep 5, 2021
- Transidentities: In the media, transphobic discourse is spreading without restraint or scruple Nov 23, 2022
- The Republicans: Tackle, decisive pass, CSC… We followed the debate between Ciotti, Pradié and Retailleau Nov 21, 2022
- Move Oppo, Vivo leads the Chinese smartphone market Apr 15, 2021
- The witcher 2: Henry Cavill announces changes for Geralt in season 2 Jul 13, 2021
- Twitter: Is Donald Trump really going to make a comeback on social media? Nov 21, 2022